Milton H. Werner
2022
In 2022, Milton H. Werner earned a total compensation of $744.1K as President and Chief Executive Officer at Inhibikase Therapeutics, a 22% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $140,250 |
|---|---|
| Option Awards | $85,865 |
| Salary | $500,833 |
| Other | $17,107 |
| Total | $744,055 |
Werner received $500.8K in salary, accounting for 67% of the total pay in 2022.
Werner also received $140.3K in non-equity incentive plan, $85.9K in option awards and $17.1K in other compensation.
Rankings
In 2022, Milton H. Werner's compensation ranked 3,647th out of 5,753 executives tracked by ExecPay. In other words, Werner earned more than 36.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,647 out of 5,753 | 37th |
Division Manufacturing | 2,075 out of 3,133 | 34th |
Major group Chemicals And Allied Products | 999 out of 1,419 | 30th |
Industry group Drugs | 936 out of 1,320 | 29th |
Industry Biological Products, Except Diagnostic Substances | 222 out of 291 | 24th |
Source: SEC filing on May 5, 2023.
Werner's colleagues
We found one more compensation record of an executive who worked with Milton H. Werner at Inhibikase Therapeutics in 2022.
2022
Joseph Frattaroli
Inhibikase Therapeutics